Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jan;22(1):9-17.
doi: 10.1080/14728222.2018.1413091. Epub 2017 Dec 10.

Rho GTPase effectors and NAD metabolism in cancer immune suppression

Affiliations
Review

Rho GTPase effectors and NAD metabolism in cancer immune suppression

Mahmoud Chaker et al. Expert Opin Ther Targets. 2018 Jan.

Abstract

Sustained proliferative signaling and de-regulated cellular bioenergetics are two of the chief hallmarks of cancer. Alterations in the Ras pathway and its downstream effectors are among the major drivers for uncontrolled cell growth in many cancers. The GTPases are one of the signaling molecules that activate crucial signal transducing pathways downstream of Ras through several effector proteins. The GTPases (GTP bound) interact with several effectors and modulate a number of different biological pathways including those that regulate cytoskeleton, cellular motility, cytokinesis, proliferation, apoptosis, transcription and nuclear signaling. Similarly, the altered glycolytic pathway, the so-called 'Warburg effect', rewires tumor cell metabolism to support the biosynthetic requirements of uncontrolled proliferation. There exists strong evidence for the critical role of the glycolytic pathway's rate limiting enzymes in promoting immunosuppression. Areas covered: We review the emerging roles of GTPase effector proteins particularly the p21 activated kinase 4 (PAK4) and nicotinamide biosynthetic pathway enzyme nicotinamide phosphoribosyltransferase (NAMPT) as signaling molecules in immune surveillance and the immune response. Expert opinion: In this expert opinion article we highlight the recent information on the role of GTPases and the metabolic enzymes on the immune microenvironment and propose some unique immune therapeutic opportunities.

Keywords: GTPase; NAD; NAMPT; NAMPT inhibitor; NAPRT; P21 activated kinases; PAK4; PAK4 inhibitor; PD-1; PD-L1; Ras; immune checkpoint.

PubMed Disclaimer

Figures

Figure 1
Figure 1. GTPase and NAD signaling mediated immune suppression mechanisms
Tumors thrive in a milieu of different types of cells including fibroblasts and collagen. Tumor stromal cells regulate the function of several types of immune cells such as Tregs, TH17, macrophages and MDSCs. Mutant ras promotes canonical RAF-MAPK-ERK-MEK pathway and also activates the Rho GTPase effector protein PAK4. RAF and PAK4 regulate the expression of pro-pro-survival signaling molecules that directly promote immune checkpoint protein PD-1 activation. PD-1 in turn block proper activation of immune surveillance molecules. NAMPT, a rate limiting enzyme in NADPH turnover, can directly activate PD-1 expression.
Figure 2
Figure 2. Dual inhibition of PAK4 and NAMPT as a feasible strategy to re-ignite a compromised tumor immune micro-environment
PAK4 signaling is active during cancer, in response to oncogenes such as Ras and mediated by Rho GTPases including Rac. Hypoxia/Warburg effect promotes the salvage biosynthesis pathway. This in turn activates immune surveillance molecules, thereby suppressing ICI activity

Similar articles

Cited by

References

    1. Lv J, Wang J, Chang S, et al. The greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism? Acta Biochim Biophys Sin (Shanghai) 2016;48:17–26. - PubMed
    1. Tufail S, Badrealam KF, Sherwani A, et al. Tissue specific heterogeneity in effector immune cell response. Front Immunol. 2013;4:254. - PMC - PubMed
    1. Kato S, Goodman A, Walavalkar V, et al. Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. Clin Cancer Res. 2017 - PMC - PubMed
    1. Potter M, Newport E, Morten KJ. The Warburg effect: 80 years on. Biochem Soc Trans. 2016;44:1499–505. - PMC - PubMed
    1. Jansen S, Gosens R, Wieland T, et al. Paving the Rho in cancer metastasis: Rho GTPases and beyond. Pharmacol Ther. 2017 - PubMed

Publication types